- Home
- PAI vs EDIT Comparison
PAI vs EDIT Comparison
Compare PAI & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAI
- EDIT
- Stock Information
- Founded
- PAI 1973
- EDIT 2013
- Country
- PAI United States
- EDIT United States
- Employees
- PAI N/A
- EDIT N/A
- Industry
- PAI Trusts Except Educational Religious and Charitable
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PAI Finance
- EDIT Health Care
- Exchange
- PAI Nasdaq
- EDIT Nasdaq
- Market Cap
- PAI 118.3M
- EDIT 99.9M
- IPO Year
- PAI N/A
- EDIT 2016
- Fundamental
- Price
- PAI $12.33
- EDIT $1.24
- Analyst Decision
- PAI
- EDIT Buy
- Analyst Count
- PAI 0
- EDIT 14
- Target Price
- PAI N/A
- EDIT $8.08
- AVG Volume (30 Days)
- PAI 25.0K
- EDIT 2.7M
- Earning Date
- PAI 01-01-0001
- EDIT 02-26-2025
- Dividend Yield
- PAI 4.78%
- EDIT N/A
- EPS Growth
- PAI N/A
- EDIT N/A
- EPS
- PAI N/A
- EDIT N/A
- Revenue
- PAI N/A
- EDIT $61,759,000.00
- Revenue This Year
- PAI N/A
- EDIT N/A
- Revenue Next Year
- PAI N/A
- EDIT N/A
- P/E Ratio
- PAI N/A
- EDIT N/A
- Revenue Growth
- PAI N/A
- EDIT 150.95
- 52 Week Low
- PAI $10.59
- EDIT $1.12
- 52 Week High
- PAI $12.63
- EDIT $11.58
- Technical
- Relative Strength Index (RSI)
- PAI 46.08
- EDIT 34.86
- Support Level
- PAI $12.12
- EDIT $1.15
- Resistance Level
- PAI $12.51
- EDIT $1.27
- Average True Range (ATR)
- PAI 0.20
- EDIT 0.10
- MACD
- PAI 0.01
- EDIT 0.04
- Stochastic Oscillator
- PAI 26.19
- EDIT 21.11
About PAI Western Asset Investment Grade Income Fund Inc.
Western Asset Investment Grade Income Fund Inc is a closed-end diversified investment company. The company designed primarily as a long-term investment and not as a trading vehicle. The fund seeks a high level of current income, consistent with prudent investment risk, through investment in a diversified portfolio of debt securities. Its portfolio is invested in securities which may be convertible into or exchangeable for, or carry warrants to purchase, common stock or other equity interests; and preferred stock.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.